Cell MedX Corp (OTCMKTS:CMXC) announced that it completed registration procedure and commenced an application course to get FDA approval for application of its eBalance equipment as Class II non-exempt device. Its clinical observational study is going as planned, and as of the last week of March, the subjects count was 21, with 18 subjects already started with initial eBalance therapies.
Cell MedX projects that the patients enrolled in trial will get their first treatment this month. Current Observational Clinical Study assesses the impact of eBalance treatment as an additional therapy, on HbA1c in diabetics. The next objectives are to observe changes from starting point and medicinal history in diabetic neuropathy, insulin sensitivity, blood pressure, diabetic foot pain and numbness, kidney function and wound healing.
McEnulty, the Chief Executive Officer of Cell MedX, mentioned that the registration process with the U.S. FDA is a significant development, and they are delighted to note that Observational Clinical Study is going as intended, which will get them closer to achieving end objective of assisting participants enhance their health and lives.
Cell MedX is in its early development phase, with a major focus on the advancement, commercialization and discovery of non-therapeutic as well as therapeutic offerings that augment general wellness and lower complications related with medical ailments such as diabetes, Parkinson’s disease and high blood pressure. It should be noted that the company’s major asset is “e-balance technology”, which is in the R&D phase to manage diabetes mellitus and related complications.
On Wednesday, the stock price of Cell MedX gained more than 1% to close the day at $0.319. The gains came at a share volume of 25,733 as against average share volume of 40,476. After the recent gain, the market cap of firm stands around $12 million. The 52-week range of CMXC stands at 0.12 – 0.46.